Advertisement
Regular Article| Volume 88, ISSUE 2, P135-141, February 2000

Download started.

Ok

Protease Inhibitor Reduces Loss of Tensile Strength in Rat Anastomosis with Peritonitis

DOI:https://doi.org/10.1006/jsre.1999.5765
Protease Inhibitor Reduces Loss of Tensile Strength in Rat Anastomosis with Peritonitis
Previous ArticleMnSOD Expression Is Increased in Metastatic Gastric Cancer
Next Articlec-Jun Does Not Mediate Hepatocyte Apoptosis Following NFκB Inhibition and Partial Hepatectomy
      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      Background. The tensile strength in intestinal anastomoses decreases postoperatively in association with degradation of the extracellular matrix, and these changes would be expected to be more intense in the presence of peritonitis.
      Materials and Methods. In this study, we investigated extracellular matrix degradation and tensile strength in a rat model of intestinal anastomosis with peritonitis. In the chemical peritonitis model, peritonitis was induced 24 h earlier with intraperitoneal HCl. A serine protease inhibitor, nafamostat mesilate (NM), was given intraperitoneally to some animals every 12 h from immediately after the operation for 3 days. Immunostaining was performed by the standard streptavidin–biotin–peroxidase method after fibronectin (Fn) and factor XIII antigen retrieval on paraformaldehyde-fixed, paraffin-embedded tissue sections.
      Results. In comparison with controls, administration of NM reduced the loss of tensile strength on Day 3 in a dose-dependent manner, and high-dose NM (20/mg/kg) significantly prevented the loss of tensile strength on Day 3 (P < 0.05). In the control group, degradation of the collagen layer in the anastomosis was associated with disappearance of Fn and factor XIII staining on Day 3. The administration of NM attenuated these changes with intense immunostaining for Fn and factor XIII seen particularly between collagen fibers on both sides of the anastomosis on Day 3. In the chemical peritonitis model, administration of NM also significantly prevented the loss of tensile strength on Day 3 without dissapperance of collagen fibers.
      Conclusion. These findings suggest that NM may be clinically useful for preventing intestinal leakage, particularly when anastomoses are performed under protease-activating conditions, such as intestinal edema and inflammation.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Surgical Research
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

      REFERENCES

        • Jönssön K.
        • Jiborn H.
        • Zederfelt B.
        Breaking strength of small intestinal anastomoses.
        Am. J. Surg. 1983; 145: 800
        • Högström H.
        • Haglund U.
        Postoperative decrease in suture holding capacity in laparotomy wounds and anastomoses.
        Acta Chir. Scand. 1985; 151: 533
        • Hawley P.R.
        • Faulk W.P.
        • Hunt T.K.
        Collagenase activity in the gastrointestinal tract.
        Br. J. Surg. 1970; 57: 896
        • Young H.L.
        • Wheeler M.H.
        Collagenase inhibition in the healing colon.
        J. R. Soc. Med. 1983; 76: 32
        • Tsutamoto Y.
        • Tani T.
        • Eguchi Y.
        Protective effect of nafamostat mesilate in early wound healing.
        J. Am. Coll. Surg. 1997; 184: 637
        • Billing A.
        • Frohlich D.
        • Assfalg M.I.
        Proteolysis of defensive proteins in peritonitis exudate: Pathobiochemical aspects and therapeutical approach.
        Biomed. Biochim. Acta. 1991; 50: 399
        • Hynes R.O.
        • Yamada K.M.
        Fibrnonectins: Multifunctional modular glycoproteins.
        J. Cell Biol. 1982; 95: 369
        • Grinnell F.
        • Feld M.
        • Minter D.
        Fibroblast adhesion to fibrinogen and fibrin substrata: Requirement for cold-insoluble globulin (plasma fibronectin).
        Cell. 1980; 19: 517
        • Egbring R.
        • Klingmann H.G.
        Factor XIII and Fibronectin: New Clinical and Biological Approaches. Med. Verl. Ges, Marburg1983
        • Kasai S.
        • Kunimoto T.
        • Nitta K.
        Cross-linking of fibrin by activated factor XIII stimulates attachment, morphological changes and proliferation of fibroblasts.
        Biomed. Res. 1983; 4: 155
        • Jönssön T.
        • Högström H.
        Neutrophil-dependent decrease in early wound margin strength.
        Arch. Surg. 1991; 126: 1423
        • Alitalo K.
        • Vaheri A.
        Pericellular matrix in malignant transformation.
        Adv. Cancer Res. 1982; 37: 111
        • Murakawa M.
        • Okamura T.
        • Shibuya T.
        Use of a synthetic protease inhibitor for the treatment of l-asparaginase-induced acute pancreatitis complicated by disseminated intravascular coagulation.
        Ann. Hematol. 1992; 64: 249
        • Hanano M.
        • Takahashi H.
        • Arakawa K.
        Consumption coagulopathy associated with left atrial thrombosis.
        Hematol. Pathol. 1991; 5: 27
        • Takemoto Y.
        • Tanaka S.
        • Tanabe J.
        Studies on the effects of primary therapy for DIC following circulatory arrest.
        Am. J. Hematol. 1986; 21: 377
        • Tani T.
        • Endo Y.
        • Yoshioka T.
        Therapeutic plasmapheresis for post-operative hepatic failure.
        Prog. Clin. Biol. Res. 1990; 337: 213

      Article info

      Identification

      DOI: https://doi.org/10.1006/jsre.1999.5765

      Copyright

      © 2000 Academic Press. Published by Elsevier Inc. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX